Melanoma Research

Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer (CMO)

Retrieved on: 
Tuesday, April 16, 2024
Melanoma Research, Cancer, CMO, HKEX, Rutgers University, Learning, Biochemistry, Hospital, Mentorship, Oncology, Research, Hematology, IIC, Tufts Medical Center, Partnership, Pharmaceutical industry, NF-1, Molecular biology, Melanoma, Environment, Certification, Science, GSK, Patient, TMB, Faculty, Harvard Medical School, Pembrolizumab, Drug development, Merck, Massachusetts General Hospital, Autoimmunity, SAN, Dana–Farber Cancer Institute

Dr. Ibrahim will provide the strategy, execution and leadership for the Oncology Global Clinical Development program.

Key Points: 
  • Dr. Ibrahim will provide the strategy, execution and leadership for the Oncology Global Clinical Development program.
  • Dr. Nageatte Ibrahim has over 11 years of oncology industry drug development experience at Merck and GSK.
  • Dr. Ibrahim possesses a Pennsylvania Medical License and ABIM Certification in Medical Oncology.
  • "We are very excited to welcome Dr. Nageatte Ibrahim onboard as our Oncology CMO in Global Clinical Development," said Dr. Michael Yu, Founder, Chairman and CEO of Innovent.

AffyImmune Therapeutics Announces Clinical and Regulatory Advisory Board to Support Development of AIC100 in Solid Tumors

Retrieved on: 
Monday, April 8, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Other Health, Clinical research, Harvard Medical School, Melanoma Research, Translational research, Surgery, Clinical, Associate, George Washington University, Patient, Regulatory affairs, University, Cancer, Doctor of Philosophy, Melanoma, Brown University, Translation, Treatment, Therapy, Drug development, Safety, FACS, University of Southern California, Biomedical Research, Pathology, Research fellow, School, Pharmaceutical industry

The CRAB will provide strategic counsel and expertise as AffyImmune advances its affinity-tuned CAR T therapeutics in clinical development.

Key Points: 
  • The CRAB will provide strategic counsel and expertise as AffyImmune advances its affinity-tuned CAR T therapeutics in clinical development.
  • “This group of distinguished scientists and advisors bring to AffyImmune invaluable CAR T drug development experience from research to commercialization,” said Sonal Gupta, MD, PhD, AffyImmune SVP and Head of Clinical Development.
  • ‘’I am honored to join Affylmmune’s Clinical and Regulatory Advisory Board and look forward to working with the other members to advance the development of novel treatments,” said Carmelo Nucera, MD, PhD.
  • Jorge J. Nieva, MD , Associate Professor of Clinical Medicine, Keck School of Medicine, University of Southern California and Section Head, Solid Tumors, USC/Norris Cancer Center.

Ribometrix Presents First c-MYC Data Validating RNA-Targeting Platform and Demonstrates Synergistic Potential of eIF4E Program at AACR 2024

Retrieved on: 
Sunday, April 7, 2024
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, SOC, Melanoma Research, Oncogene, RNA-binding protein, Patient, SVP, Neoplasm, RNA, Cancer, Messenger, Melanoma, Lung cancer, Society, IND, Immortalised cell line, AACR, Breast cancer, RBP, Therapy, Translational medicine, Vaccine

These data build on presentations at last year’s Society for Melanoma Research and San Antonio Breast Cancer Symposium .

Key Points: 
  • These data build on presentations at last year’s Society for Melanoma Research and San Antonio Breast Cancer Symposium .
  • eIF4E is a main regulator and rate limiting factor for protein synthesis and is elevated in many kinds of tumors.
  • Caused tumor regression in mouse models of aggressive melanoma, ER+ breast cancer and non-small cell lung cancers through combination treatment with SOC.
  • “The ability to target RNA-binding proteins that regulate oncogenes is a powerful modality with the potential to address cancer indications with high unmet need.

Orlucent Demonstrates Accurate, Non-Invasive Detection in vivo of Melanoma-Related Activity Using First-in-Kind Handheld Mole Imaging System

Retrieved on: 
Tuesday, January 16, 2024
Eye, Dermatology, Research, Melanoma, Scar, Oxygen, Aggression, Skin cancer, Chromatophore, Molecular imaging, Anxiety, FDA, Biopsy, Moles, Melanoma Research, Medical imaging

With the current standard of care, melanoma is identified in suspicious nevi using subjective visual clinical evaluations, during which the color, shape, and size of nevi are assessed using the ABCDE criteria (asymmetry, border, color, diameter, and evolution). When moles exhibit only one or two of these atypical features, discerning whether they could develop into melanoma becomes arduous. To avoid missing a melanoma, dermatologists rely on "when in doubt, cut it out" to manage moles which do not overtly classify as melanoma or benign -- the "grey area" lesions -- resulting in unnecessary biopsies, scarring and patient anxiety.

Key Points: 
  • Melanoma, the most lethal form of skin cancer, has long been a challenge to detect accurately, particularly those cases with the potential for aggressive behavior.
  • When moles exhibit only one or two of these atypical features, discerning whether they could develop into melanoma becomes arduous.
  • Encouraged by these findings, Orlucent is continuing research of mSFI and is preparing for FDA submission.
  • The peer-reviewed article in Pigment Cell and Melanoma Research is titled, "Molecular Skin Fluorescence Imaging: A Tool for Evaluating Early Melanoma Development," and can be found at http://doi.org/10.1111/pcmr.13159 .

Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers

Retrieved on: 
Tuesday, December 5, 2023
Chills, CRS, Melanoma, RP1, CRC, Food, Melanoma Research, RECIST, NMSC, Transplant, Diarrhea, FDA, Cytokine release syndrome, Colorectal cancer, SCCHN, Type, RP3, CRR, Fatigue, Headache, Nausea, Itch, Myocarditis, Incidence, Nivolumab, Influenza-like illness, Research, Clinical trial, Injection site reaction, Myalgia, CSCC, Skin cancer, HCC, Weakness, Society, Head, Appetite, RP2, Regeneron Pharmaceuticals, Carcinoma, Investment, Webcast, Patient, Lipase, Angiosarcoma, MCC, Vomiting, Neck, Uveal melanoma, Rash, BLA, Pharmaceutical industry

The CERPASS study was conducted under a Master Clinical Trial Collaboration and Supply Agreement with Regeneron Pharmaceuticals.

Key Points: 
  • The CERPASS study was conducted under a Master Clinical Trial Collaboration and Supply Agreement with Regeneron Pharmaceuticals.
  • The ORR was comparable between the two study groups (52.5% for RP1 plus cemiplimab vs. 51.4% for cemiplimab alone, p=0.692).
  • The registration directed anti-PD1 failed melanoma cohort from the IGNYTE clinical trial includes 140 patients and completed enrollment earlier this year.
  • RP1 monotherapy was well tolerated, and the safety profile was similar to that observed in non-immunocompromised patients with advanced skin cancers.

Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research

Retrieved on: 
Wednesday, November 8, 2023
Survival, FRCP, Research, Uveal melanoma, International Congress on Tuberculosis, Trae tha Truth, Nivolumab, University of Liverpool, Bachelor of Medicine, Bachelor of Surgery, DOR, Melanoma, Liver, Clatterbridge Cancer Centre NHS Foundation Trust, Doctor of Philosophy, Ipilimumab, Development, Lung, 8th Plenary Session of the Central Committee of the League of Communists of Serbia, Disease, Hypotension, Liver disease, Metastasis, RP2, Itch, Uvea, Immunotherapy, ORR, Chills, University, Society, Melanoma Research, Patient, Toxicity, Fatigue, Pharmaceutical industry, Fever

The data were presented by Dr. Joseph Sacco during a Plenary Session at the 20th International Congress of the Society for Melanoma Research in Philadelphia.

Key Points: 
  • The data were presented by Dr. Joseph Sacco during a Plenary Session at the 20th International Congress of the Society for Melanoma Research in Philadelphia.
  • The median duration of response (DOR) at the data cutoff was 11.47 months (range of 2.78 to 21.22 with responses ongoing).
  • RP2 was generally well tolerated both as monotherapy and in combination with nivolumab with no additive adverse events observed.
  • “These data from the trial cohort evaluating RP2 as monotherapy and in combination with nivolumab in metastatic uveal melanoma are highly promising,” said Robert Coffin, President and Chief Research & Development Officer at Replimune.

Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial

Retrieved on: 
Wednesday, November 8, 2023
Patient, FDA, Research, Pharmacology, Uveal melanoma, Regenerative Medicine Advanced Therapy, Uterine cancer, NSCLC, International Congress on Tuberculosis, Corr, Cmax, Ovarian cancer, Nivolumab, Infrared spectroscopy correlation table, TCR, Appendix, CMC, Neurotoxicity, Lung, SD, DLT, Cytokine release syndrome, Melanoma, ORR, Cell therapy, Triple-negative breast cancer, CET, PRAME, Safety, CRS, Society, Melanoma Research, Diagnosis, Today, Cytopenia, BRAF, Pharmaceutical industry, Vaccine, Medical imaging, MD

The update is focused on IMA203 GEN1 in melanoma at the recently defined recommended Phase 2 dose (RP2D) and the first clinical data for IMA203CD8 GEN2.

Key Points: 
  • The update is focused on IMA203 GEN1 in melanoma at the recently defined recommended Phase 2 dose (RP2D) and the first clinical data for IMA203CD8 GEN2.
  • In line with previous results, IMA203 GEN1 monotherapy was well tolerated at total doses up to 10x109 TCR-T cells infused.
  • The presentation is available on Immatics’ website – covering the complete data set including Phase 1a, Phase 1b Cohort A and the deprioritized Cohort B (IMA203 GEN1 combined with nivolumab).
  • Discussions with FDA to align on patient populations, trial design and CMC aspects concerning the planned Phase 2 trial are ongoing.

Immunocore announces upcoming poster presentations at SITC Annual Meeting 2023 and SMR Congress 2023

Retrieved on: 
Wednesday, November 1, 2023
Society for Immunotherapy of Cancer, TCR, Congress, SITC, Immunotherapy, Infection, SMR, Society, Cancer, Melanoma Research, Vaccine

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn.

Key Points: 
  • (OXFORDSHIRE, England & CONSHOHOCKEN, Penn.
  • & ROCKVILLE, Md, 01 November 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, will present data for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma and cutaneous melanoma at the Society for Immunotherapy of Cancer's (SITC) Annual Meeting (1st – 5th November) and the Society for Melanoma Research (SMR) Congress (6th – 9th November).
  • Across the two scientific conferences, the company will present seven posters:
    Session: Poster display, Monday November 6, 2023 – Wednesday November 8, 2023
    Session: Poster display, Monday November 6, 2023 – Wednesday November 8, 2023
    Session: Poster display, Monday November 6, 2023 – Wednesday November 8, 2023
    Session: Poster display, Monday November 6, 2023 – Wednesday November 8, 2023

Ribometrix Announces Lead Program Target and Presentation of Preclinical Data at the International Congress of the Society for Melanoma Research

Retrieved on: 
Monday, November 6, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, International Congress on Tuberculosis, Therapy, RNA, Insulin potentiation therapy, Cell proliferation, MEK, Growth, BRAF, Common, Messenger, SMR, Melanoma, Society, Cancer, Melanoma Research, Patient, Toxicity, Pharmaceutical industry, Vaccine

eIF4E is a potent oncogene that promotes cell growth by regulating the synthesis of oncoproteins known to drive abnormal cell proliferation and tumorigenesis.

Key Points: 
  • eIF4E is a potent oncogene that promotes cell growth by regulating the synthesis of oncoproteins known to drive abnormal cell proliferation and tumorigenesis.
  • Common cancer drivers, such as mutant versions of BRAF/MEK and PI3K/AKT, are reliant on activation of eIF4E for the production of oncoproteins that lead to uncontrolled cell proliferation.
  • Ribometrix is evaluating its portfolio of eIF4E inhibitors in preclinical studies and plans to select a development candidate in 2024.
  • Additional preclinical data in other indications will be presented at upcoming medical conferences, including the San Antonio Breast Cancer Symposium in December 2023.

Provectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentations at Society for Melanoma Research (SMR) 2023 Congress

Retrieved on: 
Tuesday, August 1, 2023
Abstract, SMR, Congress, Liver, OTCQB, Uveal melanoma, Society, Melanoma Research, Pharmaceutical industry, Computer data storage, Medical imaging

KNOXVILLE, TN, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from ongoing clinical trials of investigational cancer immunotherapy PV-10 (rose bengal sodium) for the combination therapy treatments of uveal melanoma metastatic to the liver (NCT00986661) and Stage III-IV cutaneous melanoma (NCT02557321) will be presented on two poster presentations at the Society for Melanoma Research (SMR) 2023 Congress (the SMR annual meeting) to be held in Philadelphia, PA from November 6-9.

Key Points: 
  • KNOXVILLE, TN, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from ongoing clinical trials of investigational cancer immunotherapy PV-10 (rose bengal sodium) for the combination therapy treatments of uveal melanoma metastatic to the liver (NCT00986661) and Stage III-IV cutaneous melanoma (NCT02557321) will be presented on two poster presentations at the Society for Melanoma Research (SMR) 2023 Congress (the SMR annual meeting) to be held in Philadelphia, PA from November 6-9.
  • The two accepted abstracts are: